The flu treatment Relenza looks unlikely to be made available on the National
Health Service in Britain. As ¿ìè¶ÌÊÓƵ went to press, the National
Institute for Clinical Excellence was thought to have advised against releasing
the drug, which limits symptoms and hastens recovery. Richard Sykes, chairman of
Glaxo Wellcome, the drug’s maker, is incensed. Yet a company data sheet prepared
in August states that the drug has yet to be shown to work in chronically ill or
immunocompromised patients, who are most at risk from complications of the
flu.
More from ¿ìè¶ÌÊÓƵ
Explore the latest news, articles and features
Popular articles
Trending ¿ìè¶ÌÊÓƵ articles
1
The best new science-fiction books of June 2026
2
Pancreatic cancer halted by virus injection in three patients
3
Does gravity create reality? A shocking path to a theory of everything
4
Glaciers in the 'roof of the world' have suddenly started melting
5
First quantum grandfather clock could probe where gravity comes from
6
Q-Day could destroy bitcoin – and our retirement savings
7
The ‘doomsday’ glacier’s giant ice shelf is about to break away
8
Surprising male G-spot found in most detailed study of the penis yet
9
Mathematicians stunned by AI's biggest breakthrough in mathematics yet
10
Photons behave very strangely if you try to cut them
